The Floodlight MS app, used to track disease progression in people with multiple sclerosis, has been deemed cost-effective in ...

TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for ...

WHEN life gave Lina Nielsen lemons, she sprinted straight to the Olympics.  The 28-year-old was diagnosed with multiple sclerosis at 17 years old, leaving her terrified of disability. Doctors gave ...

A Phase 2 clinical trial testing obexelimab in adults with relapsing types of multiple sclerosis is now recruiting ...

Rebif Market Report 2025 - Epidemiology, Pipeline Analysis, Market Size, Trends, And Global Forecast 2034 The Business Research Company's G ...

February 10-11: BIO CEO & Investor Conference 2025. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in one-on-one meetings at this conference, taking place in New York.

in Ireland for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease.1 BRIUMVI® is a novel monoclonal antibody that targets a unique epitope on CD20-expressing ...

There are relapsing-remitting and progressive types of MS, but the course is rarely predictable. Researchers still don’t fully understand the cause of MS or why the rate of progression is so ...

Therapy with cladribine tablets was evaluated as a short-course regimen for RRMS in the Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study. [46–49] CLARITY was a Phase III ...

Most children with MS eventually progress from relapsing-remitting type to secondary progressive MS. While every person with pediatric MS is different, the transition usually happens around 40 ...

Relapsing-remitting MS (RRMS) is the most common type of MS among the million ... A study in American Family Physician found DMTs “has been shown to slow disease progression and disability; options ...